Daily Biotech Movers — 2026-10-30: Two Companies Repriced on Earnings While the Rest of the Cohort Repriced on Liquidity

Friday, October 30, 2026 was a washout that the index did not report. Of the 558 companies in our cohort with a usable close, 102 finished higher against 456 lower — a ratio of 0.22-to-1, the narrowest breadth we have recorded in weeks — on a median move of -2.91% and a mean of -3.32%, with a standard deviation of 5.98%. 178 names moved at least 5%, and the split inside that group is the whole story of the session: 13 up, 165 down. 195 cleared the anomaly filter, 44 turned over at least twice their 30-day average volume and 14 at least three times.

The proxies said something milder. The health care sector proxy rose 0.43%, the large-cap biotech proxy fell 0.11%, the small-cap biotech proxy fell 1.17%, and the S&P 500 fell 1.77%. Read that ladder against Thursday’s and the rotation has not reversed — it has steepened. On October 29 the sector proxy rose 2.41% while the small-cap proxy managed 0.18%; today the sector proxy stayed green while the small-cap proxy went red and the median stock in our cohort fell nearly three percent. The gap between the sector and the median — 3.34 percentage points — is the widest divergence in the recent record, and it is not a biotech story. It is a market-cap story.

The macro context explains the shape. The broad tape sold off on disappointing earnings from two of the largest technology companies in the index, and money that had to stay in equities went to the defensive end of health care rather than to the speculative end of biotechnology. That is why a sector proxy can close up 0.43% on a day when 456 of 558 small and mid-cap life-sciences names closed lower. The cohort we follow is not the sector; it is the part of the sector that lives off future cash flows rather than current ones, and on a day when the cost of waiting rises, that is the part that gets sold.

The industry buckets show it cleanly. Generic drugs averaged +1.43% across five names — the only positive bucket with more than four constituents — followed by devices, imaging at -1.76% across eight and RNA, peptide and gene therapy at -2.15% across 26. Below that the board is uniformly red: small molecule pharma -3.08% across 147, diagnostics -3.08% across 30, biologics -3.46% across 84, drug delivery -3.53% across 29, stem cells and cellular therapy -3.57% across 23, antibodies -3.98% across 42, devices, surgical -4.47% across 29, and at the bottom genetics and genomics at -8.58% across seven and AI and machine learning at -5.82% across five. (The -5.09% row tagged New England is a geographic grouping, not an industry.)

The 6 Classes of Mover Signal

Every anomaly-flagged move is assigned to one of six classes, and the class is what separates information from mechanics. Class 1 — halt-release: a name resumes trading after a regulatory or news halt and gaps to a new equilibrium. Class 2 — single-stock binary catalyst: a clinical readout, regulatory decision, earnings print or programme failure resets the equity’s entire valuation in one session. Class 3 — buyout and strategic capital: an acquisition, tender, divestiture, licensing deal, financing, registration or split event reprices the float against a control value or against the supply of paper. Class 4 — sector rotation: the name moves with its bucket rather than with its own news. Class 5 — sell-the-news: a disclosure is sold because the outcome was already in the price. Class 6 — stealth accumulation or distribution: the price barely moves while turnover runs multiples of normal.

Friday’s board was two clean Class 2 prints — CareDx and Regeneron, both earnings, both to new 52-week highs — one Class 2 clinical failure in Acumen Pharmaceuticals, one Class 5 supply-overhang slide in Gyre Therapeutics, one Class 1/Class 5 mechanical unwind in Karyopharm, and one name with no clean catalyst at all in Annovis Bio, whose only same-day disclosure pointed the opposite way from its tape.

What makes the day worth writing about is how thin the information content was relative to the size of the move. Two of 558 names repriced because their earnings power changed. Three more repriced because the supply of their shares changed, or because a squeeze ran out of buyers. That is a 0.4% hit rate on fundamental repricing in a session that produced 178 five-percent moves. On a day like this, the leaderboard is mostly a report about liquidity — who needed to sell, and who was allowed to.

Top 3 Winners — What Drove Them

CDNA — CareDx, +22.22% to $87.41 on 2.48x volume

CareDx closed at $87.41, up 22.22%, on 3.55 million shares against a three-month average near 1.44 million — a 2.48x volume ratio — after gapping from a $71.52 close and trading as high as $90.87. It cleared its prior 52-week range of $14.22 to $73.43 and closed near the high of a range that has now roughly sextupled in twelve months (CareDx — Q3 2026 results, TIKR — CareDx soars on Q3 beat and guidance raise, Investing.com — earnings call transcript).

The catalyst is a Class 2 print released after the close on October 29. Revenue of $139.36 million, up 39% year over year and roughly $17 million above the $122 million consensus; adjusted earnings of $0.70 per share against $0.26 expected; GAAP net income of $19.3 million against $1.7 million a year earlier; and adjusted EBITDA of $30.5 million, nearly matching the company’s entire 2025 total. Testing services revenue rose 65% to $119.2 million on 75,900 tests, up 51%, including the first full quarter of specialty-oncology volume following the July 1 close of the Naveris acquisition.

What turned a beat into a re-rating was the guidance. Full-year 2026 revenue was lifted to $520–530 million from $490–500 million and adjusted EBITDA to $90–100 million from $66–78 million — a midpoint $30 million above the prior range and about 6% above the $495 million consensus — and Canaccord lifted its target to $99 from $80 while BTIG went to $92 from $81 (TipRanks — why CDNA is up 18%, Market Chameleon — guidance jumps to $520–530M).

The honest caveat is that $15 million of the quarter’s testing revenue came from tests run in earlier periods, against $6 million a year earlier — so the raise, not the beat, is the signal, and management’s own framing is that testing services grew about 58% excluding that catch-up. Cash from operations fell to $13 million from $37 million, and at 52.1 million shares the equity now carries a valuation around $4.6 billion against roughly $525 million of forward revenue — a multiple that requires AlloHeme’s first-quarter 2027 launch and the Epic Aura oncology integrations to land as described.

REGN — Regeneron, +13.33% to $927.89 on 4.22x volume

Regeneron closed at $927.89, up 13.33%, on 2.87 million shares against a 30-day average near 681,000 — a 4.22x volume ratio — finishing within $8 of its $935.35 intraday high and clearing a prior 52-week range of $591.52 to $859.34, while the S&P 500 fell 1.77% (Seeking Alpha — Regeneron posts Q3 beat after 36% growth, FinancialContent — REGN trades up, here is why, GuruFocus — REGN surges despite S&P decline).

The Class 2 catalyst landed before the open: third-quarter revenue of $5.1 billion, up 36% year over year, with non-GAAP diluted earnings of $20.07 per share, up 70%, and record net sales for Dupixent, Eylea HD and Libtayo. Three secondary items compounded it — a BARDA/ASPR extension of the Inmazeb Ebola supply contract through 2031 worth roughly $270 million, a positive CHMP opinion for an every-six-weeks Libtayo dosing schedule in Europe, and a wave of target increases: TD Cowen to $980 on stronger Eylea modelling and higher-dose Eylea HD, Canaccord to $922 on Dupixent strength and a C5 programme catalyst with a generalised myasthenia gravis launch planned for the fourth quarter, and Piper Sandler to $865 (StocksToTrade — bullish data and targets pile up, ChartExchange — REGN news for 2026-10-30).

The detail that matters for follow-through is the five-day change going in: -0.04%. Regeneron did not arrive at this print having run; it arrived flat, and it repriced in one session on a number that changed the earnings base. GuruFocus’s model value of $913.18 against an intrinsic estimate of $941.27 puts the close only modestly below fair value on its arithmetic — a useful reminder that a 13% day in a $900 stock is a legitimate re-rating rather than a squeeze, and that the analysts raising targets are chasing rather than leading.

ANVS — Annovis Bio, +12.25% to $1.145 on 1.97x volume

Annovis Bio rose 12.25% to $1.145 on 1.50 million shares against a 30-day average near 759,000 — a 1.97x volume ratio — closing near the top of a $1.01–$1.17 range and about 23% above a 52-week low of $0.93, in a band that runs to $5.50. We flag this name as having no clean catalyst. The only disclosure dated October 30 points the other way (GlobeNewswire via Morningstar — NYSE continued listing notice, Investing.com — Annovis receives non-compliance notice, Kalkine — 8-K disclosing the notice).

On October 29 the New York Stock Exchange notified the company that it no longer complies with Section 802.01B of the Listed Company Manual, because its 30-trading-day average market capitalisation was approximately $48.4 million as of October 28 — below the $50 million threshold — while its last reported stockholders’ deficit was approximately $(4.3) million at June 30. The company has 45 days to submit a compliance plan and up to nine months to cure, trades with a .BC designation in the interim, and faces accelerated delisting if the stock trades below $0.10.

A sub-$50 million market capitalisation with negative stockholders’ equity is not a fundamental bid, and the tape going the other way is the tell that this is not information. The dated positive context is older: on October 22 the company said it will make three presentations on buntanetap at the CTAD conference in Boston on November 16–19, with its pivotal Phase 3 early-Alzheimer’s readout guided to the first quarter of 2027 after a fourth-quarter database lock, and Maxim reiterating Buy with an $8 target (GlobeNewswire — Annovis to attend CTAD 2026, TipRanks via NewsBreak — Buy reiterated into CTAD).

The honest reading is a low-float bounce off the bottom of the range on below-2x volume, for reasons the tape does not disclose. Flagged as prior-cycle / mechanical — and excluded from this synthesis as evidence of anything except how thin the bid is in a name this size.

Top 3 Losers — What Drove Them

ABOS — Acumen Pharmaceuticals, -90.83% to $0.2101 on 96.04x volume

Acumen lost 90.83% to $0.2101 on 67.5 million shares against a 30-day average near 703,000 — a 96.04x volume ratio, the largest liquidity event in the entire 558-name universe — gapping from a $2.29 close to a $0.35 high and closing at the low of the day, 86% below the prior 52-week floor of $1.50 (GlobeNewswire via Morningstar — ALTITUDE-AD topline, RTTNews — shares drop 89%, Seeking Alpha — Acumen falls on trial setback).

This is the cleanest Class 2 clinical failure on the board. The Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in 542 patients with early Alzheimer’s disease missed its primary endpoint — change from baseline in the integrated Alzheimer’s Disease Rating Scale at 18 months versus placebo — at both the 35 mg/kg and 50 mg/kg doses, and failed statistical significance on key secondaries including CDR-SB, with no meaningful separation from placebo in either arm.

The mechanistic detail makes the failure more complete, not less. Amyloid plaque load fell significantly on PET SUVr at both 36 and 76 weeks, and roughly 10% of treated participants developed ARIA-E. The drug engaged its target and the target did not translate into cognition — which is precisely the hypothesis the company was built to test, since it was formed in 1996 on the argument that soluble oligomers rather than plaque are the driver. Management will cease sabirnetug development including the open-label extension, implement cash-conservation measures, and evaluate strategic options including its Enhanced Brain Delivery programme, whose lead candidate IND was targeted for mid-2027.

The arithmetic explains the violence. With $78.6 million of cash and marketable securities at September 30 guiding operations only into early 2027, a close of $0.21 on roughly 72 million shares values the entire company near $15 million — below the cash. When a clinical-stage equity trades under its net cash, the market is no longer pricing a pipeline against a probability of approval; it is pricing burn against a liquidation, and it is telling you it expects the cash to be spent before anything else is proven. Citi cut the stock to Neutral with a $1.00 target the same morning (MarketBeat — Citi downgrade). The five-day change going in was +11.2%, so the print arrived into a stock that was already recovering — which is why the gap was twice the size of any reasonable prior probability of failure.

GYRE — Gyre Therapeutics, -28.94% to $4.555 on 2.64x volume

Gyre gapped from a $6.41 close to a $6.30 high and closed at $4.555, down 28.94%, on 394,071 shares against a 30-day average near 149,000 — a 2.64x volume ratio — finishing 30% below its prior 52-week low of $5.44 (MarketBeat — GYRE shares gap down, Gyre IR — press releases, American Banking News — GYRE reports November 6).

We flag this name as having no clean catalyst. There is no company release dated October 30 — the investor-relations record’s most recent item is September 3, and third-quarter results are not due until November 6, with consensus at a loss of $0.15 per share on $28.40 million of revenue. The same-day sell-side notes recycle the second-quarter miss — a loss of $0.12 per share against $0.06 expected on revenue of $29.11 million that beat the $26.49 million consensus — which was reported on August 7, and they carry a consensus rating of Reduce on one Hold and one Sell.

What the tape is actually discounting is supply, and the supply is documented. The May 4 all-stock acquisition of Cullgen valued the target at roughly $300 million and issued 14.45 million new Gyre common shares plus Series B preferred convertible into five common shares each, subject to a 19.99% cap and individual ownership limits, with a resale registration statement required within 45 days of closing and lock-ups staggering in thirds at six, twelve and eighteen months (SEC — Gyre Form 10-Q for the quarter ended June 30, 2026, StockTitan — Schedule 13D/A on the Cullgen merger).

Layer on a JPY 20 billion term loan secured by Gyre stock and China commercial revenue that must fund a U.S. pipeline pivot, and the picture is a company whose holder base is being diluted while its catalysts — the November 6 print and the F351 NDA under priority review in China — sit a week away. The five-day change going in was +9.4%, after declines of 5.0% on October 16, 4.4% on October 21 and 8.9% on October 29: Friday accelerated an existing slide rather than starting one. Flagged as prior-cycle / supply-overhang.

KPTI — Karyopharm Therapeutics, -24.76% to $0.662 on 0.95x volume

Karyopharm lost 24.76% to $0.662 on 3.50 million shares — below its 30-day average of 3.68 million — after trading between $0.58 and $0.90, closing 79% above its 52-week low of $0.31 with a five-day change still at +61.1% (Fiscal.ai — KPTI daily prices, Public.com — KPTI after-hours, Karyopharm — sNDA submission).

We flag this name as having no clean same-day catalyst. There is no disclosure dated October 30; what the tape shows is the unwind of a squeeze. The stock closed at $0.48 on October 27, then at $0.8321 on October 28 on 52.8 million shares — a single session’s turnover of more than twice the company’s reported 22.7 million shares outstanding — held $0.8798 on October 29, gave back a quarter of it on Friday, and then rebounded 40% to $0.87 in after-hours trading. That is not a repricing; it is a low-float tape finding a different price every twelve hours.

The dated fundamental driver is a filing, not a result. On August 31 the company submitted a supplemental new drug application for Xpovio (selinexor) plus ruxolitinib in JAK-inhibitor-naive myelofibrosis under the accelerated approval pathway, requested priority review, and said it expects notice of FDA filing acceptance and review timelines in the fourth quarter of 2026 following the agency’s 60-day filing review — a clock that runs out at the end of October (OncLive — FDA receives sNDA, The APO — sNDA under accelerated approval).

The underlying data are genuinely strong: the Phase 3 SENTRY trial showed SVR35 at week 24 in 49.8% of the combination arm against 28.0% on ruxolitinib alone, an odds ratio of 2.58 with p<0.0001, on a programme the company sizes at roughly $1 billion of peak sales. But the balance sheet is the constraint — a commercial-stage company with 228 employees, trailing earnings of -$14.40 per share, negative book value per share, and a cash position that has required lender forbearance, trading under a dollar. A 73% two-day squeeze followed by a 25% give-back on below-average volume is a mechanical event. Flagged as prior-cycle / mechanical.

The Cross-Cutting Pattern

The proxies named the rotation again, and this time they named it against the cohort. Health care +0.43%, large-cap biotech -0.11%, small-cap biotech -1.17%, our median -2.91%, S&P 500 -1.77%. Three sessions ago the sector proxy and the small-cap proxy were moving together. Thursday they separated. Friday they separated further and the median fell through both. That progression — sector green, large-cap flat, small-cap red, median worse — is what a cap-ladder rotation looks like when it is no longer about health care at all but about duration. In a tape where the discount rate is being repriced by a technology-led selloff, the assets furthest from cash flow fall first and hardest.

The second pattern is the shape of the tail. 165 of 178 five-percent movers were decliners, and the average decliner lost 4.74% against an average advancer’s 2.99%. A 13-to-1 downside skew inside the big-mover set is not a normal distribution of news; it is a market where the marginal seller is indifferent to the individual story. That is why the two names at the top of the board both report earnings and the three at the bottom all involve shares rather than science — Acumen’s failure destroyed value, but Gyre’s slide and Karyopharm’s unwound squeeze were about how much paper exists and who holds it.

The third observation is that the day’s only genuine information was negative and binary, and the market punished it with unusual efficiency. Acumen did not drift 40% lower over a week; it went to below net cash in a single session on 96x volume. Meanwhile the one piece of genuinely positive information in the small-cap end — Karyopharm’s SENTRY data, which is as clean a Phase 3 result as this cohort produced all year — could not hold a bid because the company cannot fund itself past the readout. Good data plus a broken balance sheet trades like no data at all. That is the lesson this session keeps teaching, and Friday taught it twice.

The 5 Data Points That Matter

1. Relative performance versus the sector mean is where the information lives. The cohort median fell 2.91% against a sector proxy that rose 0.43% — a 3.34-point gap. CareDx beat its own bucket by more than 25 points (diagnostics averaged -3.08%), Regeneron by more than 13 (biologics -3.46%), Acumen by 87 (small molecule pharma -3.08%). When a stock’s move is 25 points away from its bucket, the bucket is irrelevant and the story is company-specific. When it is three points away, you are reading the market, not the company.

2. Volume separates conviction from noise, and it did so violently. 44 names traded at least twice their 30-day average and 14 at least three times. The largest print on the board was Acumen’s 96.04x — 67.5 million shares in a company with a $15 million market capitalisation, which is roughly four times the entire equity value changing hands in one session. Against that, CareDx’s 2.48x on 3.55 million shares and Regeneron’s 4.22x on 2.87 million are the only two prints on the leaderboard where the volume represents institutions repositioning on new information rather than mechanics. Karyopharm’s 0.95x — below average — is the tell that its 25% decline required no selling pressure at all, only the absence of buyers.

3. Five-day momentum shows who arrived out of nowhere. Going in: CDNA +3.4%, REGN -0.04%, ANVS +2.9%, ABOS +11.2%, GYRE +9.4%, KPTI +61.1%. Only two of the six were flat or near-flat into the session, and those two — CareDx and Regeneron — are the two that repriced on fundamentals and closed at new highs. The four that were already moving are the four that reversed or unwound. That relationship is not a coincidence: a name that has already run is a name where the marginal buyer has already bought.

4. Range position is the most honest single number on the board. CDNA at $87.41 closed above a prior $73.43 high. REGN at $927.89 closed above a prior $859.34 high. ABOS at $0.2101 closed 86% below a prior $1.50 floor. GYRE at $4.555 closed 16% below a prior $5.44 floor. ANVS at $1.145 sits in the bottom quarter of a $0.93–$5.50 band. KPTI at $0.662 sits near the bottom of a $0.31–$10.99 range whose width is an artefact of a collapsing equity, not a business cycle. Four of six made new highs or new lows, and not one of them was ambiguous about direction.

5. Cash and dilution is where the two ends of the board diverge cleanly. CareDx raised guidance to $520–530 million of revenue and $90–100 million of adjusted EBITDA and does not need to sell stock to get there. Regeneron grew revenue 36% and lifted earnings per share 70% while buying back nothing and needing nothing. Against that, Acumen has $78.6 million of cash, a burn rate that exhausts it in early 2027, and a $15 million market capitalisation — the market has already priced the raise and the wind-down simultaneously. Gyre issued 14.45 million shares plus convertible preferred eight weeks ago and still carries a term loan secured by its own stock. Karyopharm has negative book value per share and traded 2.3 times its share count in a single session. The common thread is not leverage and it is not cash: it is that four of the six are net consumers of capital, and the two that are not were the two that went up for reasons a fundamental investor would recognise.

What This Synthesis Will and Will Not Tell You

This is a one-session sample of 558 companies out of the 600 we attempt; two names were skipped and thirty quote requests did not return a usable print. Nothing here is a recommendation, and one day of price action is a weak evidentiary base for any conclusion about a company’s value — Thursday’s leaderboard was an up-cap rotation of earnings beats, and today’s is the same rotation taken one step further down the ladder.

What the synthesis will tell you is where the session’s information was concentrated, which moves had turnover behind them, and which class of signal each extreme belongs to. CareDx’s +22.22% is a 39% revenue beat plus a $30 million guidance raise and a new 52-week high. Regeneron’s +13.33% is a 36% revenue quarter, a 70% earnings-per-share increase and a new 52-week high on a day the S&P fell 1.77%. Annovis’s +12.25% is unattributed and runs against its only same-day disclosure — a NYSE listing deficiency notice — so we exclude it as evidence. Acumen’s -90.83% is a Phase 2 Alzheimer’s failure that took the equity below net cash. Gyre’s -28.94% is a supply overhang into a November 6 print, with no release to point at. Karyopharm’s -24.76% is the unwind of a 73% squeeze on below-average volume, with a genuine FDA filing decision pending in the same quarter.

What it will not tell you is whether any of those readings survive the week. We do not model intraday order flow, borrow availability, short interest changes or institutional positioning, and we cannot see the private conversations that set expectations into a print. A cap-ladder rotation can last two sessions or two weeks, and the names at the bottom of today’s board are the ones most likely to bounce hardest if it reverses — which is exactly what happened to Thursday’s losers on the two prior sessions. Three of today’s six have a dated event within a fortnight: Gyre reports on November 6, Annovis presents at CTAD on November 16–19, and Karyopharm’s FDA filing decision is due inside the fourth quarter. Those dates, not today’s percentages, will discriminate between the readings. We will be back Monday with the follow-through, not a forecast.

This analysis is compiled from public market data and public company disclosures for informational purposes only. It is not investment advice, an offer, or a solicitation. Positions in individual securities carry risk of loss, including total loss. Readers should conduct their own due diligence.